



## Clinical trial results:

### A Prospective, Multi-centre, Single-Arm, Open Label Study of the Long term Use of a LHRH Agonist (Decapeptyl® SR, 11.25 mg) in Combination with Livial® Add-back Therapy in the Management of Chronic Cyclical Pelvic Pain in Pre-Menopausal Women

#### Summary

EudraCT number	2007-001159-20
Trial protocol	GB
Global end of trial date	09 May 2016

#### Results information

Result version number	v1 (current)
This version publication date	22 September 2018
First version publication date	22 September 2018

#### Trial information

##### Trial identification

Sponsor protocol code	STH14404
-----------------------	----------

##### Additional study identifiers

ISRCTN number	ISRCTN19040577
ClinicalTrials.gov id (NCT number)	NCT00735852
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Sheffield Teaching Hospitals NHS Foundation Trust
Sponsor organisation address	8 Beech Hill Road, Sheffield, United Kingdom, S10 2SB
Public contact	Mr Mostafa Metwally, Sheffield Teaching Hospitals NHS Foundation Trust, 0114 2268092, mostafa.metwally@sth.nhs.uk
Scientific contact	Mr Mostafa Metwally, Sheffield Teaching Hospitals NHS Foundation Trust, 0114 2268092, mostafa.metwally@sth.nhs.uk

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	09 May 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	09 May 2016
Global end of trial reached?	Yes
Global end of trial date	09 May 2016
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To assess the impact of treatment with Decapeptyl SR plus Tibolone on CCPP throughout the 24 month treatment period. Changes will be determined by comparison to Baseline. Pain will be assessed using the Chronic Pain Grade (CPG) Questionnaire

Protection of trial subjects:

No specific measures were in place as these were not deemed necessary.

Background therapy:

Livial was used as an add back therapy to help prevent bone loss and to help to minimise the potential side effects of the decapeptyl (menopausal symptoms).

Evidence for comparator:

No comparators were used.

Actual start date of recruitment	18 December 2008
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	United Kingdom: 31
Worldwide total number of subjects	31
EEA total number of subjects	31

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	31
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

Recruitment period December 2008- December 2013

### Pre-assignment

Screening details: -

### Pre-assignment period milestones

Number of subjects started	31
Number of subjects completed	27

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Consent withdrawn by subject: 1
Reason: Number of subjects	Physician decision: 1
Reason: Number of subjects	screen fail: 1
Reason: Number of subjects	lost to follow up: 1

### Period 1

Period 1 title	Baseline
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	treatment
-----------	-----------

Arm description:

commenced unblinded open label treatment

Arm type	Experimental
Investigational medicinal product name	Decapeptyl
Investigational medicinal product code	L02AE04
Other name	Triptorelin
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Decapeptyl 11.25 mg given IM 3 monthly for 2 years.

Prepared by mixing powder with solution immediately prior to use

Number of subjects in period 1 <sup>[1]</sup>	treatment
Started	27
Completed	27

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 4 patients left the study after being consented. One was a screen fail, one withdrew consent, one was physicians decision to withdraw the patient and one was lost to follow up.

## Period 2

Period 2 title	24 months
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

<b>Arm title</b>	treatment
------------------	-----------

Arm description:

Unblinded open label treatment

Arm type	Experimental
Investigational medicinal product name	Decapeptyl
Investigational medicinal product code	L02AE04
Other name	Triptorelin
Pharmaceutical forms	Powder for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

Decapeptyl 11.25 mg given IM 3 monthly for 2 years.

Prepared by mixing powder with solution immediately prior to use

Number of subjects in period 2	treatment
Started	27
Completed	13
Not completed	14
Consent withdrawn by subject	4
Adverse event, non-fatal	4
Lack of efficacy	6

## Period 3

Period 3 title	30 Months
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

## Arms

<b>Arm title</b>	Follow up
Arm description:	
Follow up	
Arm type	Follow up
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 3</b>	Follow up
Started	13
Completed	13

## Baseline characteristics

---

### Reporting groups

Reporting group title	Baseline
-----------------------	----------

Reporting group description: -

Reporting group values	Baseline	Total	
Number of subjects	27	27	
Age categorical			
women aged 18- 45 years inclusive			
Units: Subjects			
Adult women 18-45	27	27	
Gender categorical			
Units: Subjects			
Female	27	27	

## End points

### End points reporting groups

Reporting group title	treatment
Reporting group description: commenced unblinded open label treatment	
Reporting group title	treatment
Reporting group description: Unblinded open label treatment	
Reporting group title	Follow up
Reporting group description: Follow up	

### Primary: Pain score at 24 months of treatment compared to baseline

End point title	Pain score at 24 months of treatment compared to baseline <sup>[1]</sup>
End point description: Pain scores at 24 months were compared to pain scores at baseline using the CPG questionnaire	
End point type	Primary
End point timeframe: 24 months	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No further statistical analyses are available from the study team

End point values	treatment	treatment		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	13		
Units: Pain score out of 100				
median (full range (min-max))	66.7 (30 to 93)	13.33 (0 to 36.3)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Pain score at month 30 compared to month 24

End point title	Pain score at month 30 compared to month 24
End point description: Pain scores at 30 months were compared to scores at 24 months (i.e. 6 months following end of treatment)	
End point type	Secondary
End point timeframe: 30 months	



<b>End point values</b>	treatment	Follow up		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	13		
Units: pain score				
median (full range (min-max))	13.33 (0 to 36.3)	56.66 (6 to 80)		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

until 28 days after last administration of study drug

Adverse event reporting additional description:

patients issued with study diary to record adverse events. In addition patients were asked at each study visit to report any adverse events.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

### Reporting groups

Reporting group title	Decapeptyl® SR, 11.25 mg
-----------------------	--------------------------

Reporting group description:

All study participants received the same dose for the same time period.

Serious adverse events	Decapeptyl® SR, 11.25 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 27 (22.22%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Head injury	Additional description: accident - banged head. due to presence of intracranial shunt was admitted overnight for observation		
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Ventriculo-peritoneal shunt	Additional description: Patient experienced multiple SAEs due to inpatient hospitalisation to insert and revise placement of intracranial shunt. This was due to pre existing raised intracranial pressure.		
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Haemorrhage intracranial			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Pelvic pain			
subjects affected / exposed	4 / 27 (14.81%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pneumonia			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Urinary tract infection			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Post procedural complication	Additional description: Umbilical wound infection post surgery for placement of intracranial stent.		
subjects affected / exposed	1 / 27 (3.70%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Decapeptyl® SR, 11.25 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	27 / 27 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Pyogenic granuloma subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		
Vascular disorders Hot flush subjects affected / exposed occurrences (all)	9 / 27 (33.33%) 10		
Surgical and medical procedures Tooth extraction subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		
General disorders and administration site conditions Injection site pain subjects affected / exposed occurrences (all)  Lethargy subjects affected / exposed occurrences (all)  Pyrexia subjects affected / exposed occurrences (all)  general malaise subjects affected / exposed occurrences (all)  swelling of hands subjects affected / exposed occurrences (all)  swelling of feet subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 2  4 / 27 (14.81%) 5  1 / 27 (3.70%) 1  3 / 27 (11.11%) 3  1 / 27 (3.70%) 1  1 / 27 (3.70%) 1		
Immune system disorders hayfever subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 3		
Reproductive system and breast disorders			

vaginal bleeding			
subjects affected / exposed	13 / 27 (48.15%)		
occurrences (all)	23		
Dyspareunia			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	2		
endometrioma			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Ovarian cyst			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
Pelvic pain			
subjects affected / exposed	11 / 27 (40.74%)		
occurrences (all)	24		
Breast tenderness			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
Dysmenorrhoea			
subjects affected / exposed	4 / 27 (14.81%)		
occurrences (all)	5		
Vaginal discharge			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
sore throat			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	3		
dry cough			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
sinus pain			
subjects affected / exposed	5 / 27 (18.52%)		
occurrences (all)	7		
nose bleed			

subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	6		
Insomnia			
subjects affected / exposed	6 / 27 (22.22%)		
occurrences (all)	8		
Mood swings			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Loss of libido			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
Depression			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
low mood			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	3		
Investigations			
bone density decreased			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
lumbar puncture			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	2		
intracranial pressure monitoring			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
blood pressure raised			
subjects affected / exposed	4 / 27 (14.81%)		
occurrences (all)	4		
weight gain			

subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 3		
Injury, poisoning and procedural complications wrist sprain subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		
Nervous system disorders Headache subjects affected / exposed occurrences (all)  Carpal tunnel syndrome subjects affected / exposed occurrences (all)  Migraine subjects affected / exposed occurrences (all)  trapped nerve subjects affected / exposed occurrences (all)  Dizziness subjects affected / exposed occurrences (all)  faint subjects affected / exposed occurrences (all)  pins and needles subjects affected / exposed occurrences (all)	14 / 27 (51.85%) 35  1 / 27 (3.70%) 1  3 / 27 (11.11%) 5  1 / 27 (3.70%) 1  1 / 27 (3.70%) 1  1 / 27 (3.70%) 1  1 / 27 (3.70%) 1		
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		
Ear and labyrinth disorders ear ache subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		

perforated ear drum subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		
Eye disorders dry eyes subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	5 / 27 (18.52%) 5		
Nausea subjects affected / exposed occurrences (all)	4 / 27 (14.81%) 4		
upset stomach subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 8		
benign gastric polyp subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		
abdominal bloating subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 5		
Constipation subjects affected / exposed occurrences (all)	3 / 27 (11.11%) 3		
heartburn subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2		
indigestion subjects affected / exposed occurrences (all)	2 / 27 (7.41%) 2		
food poisoning subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		
upper abdominal pain			



<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 27 (3.70%)</p> <p>1</p>		
<p>rectal bleeding</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 27 (3.70%)</p> <p>1</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>itchy skin</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Acne</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Night sweats</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>skin rash</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Swelling face</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 27 (7.41%)</p> <p>3</p> <p>4 / 27 (14.81%)</p> <p>9</p> <p>2 / 27 (7.41%)</p> <p>2</p> <p>2 / 27 (7.41%)</p> <p>2</p> <p>1 / 27 (3.70%)</p> <p>1</p>		
<p>Renal and urinary disorders</p> <p>frequency of micturition</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>kidney pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 27 (3.70%)</p> <p>1</p> <p>1 / 27 (3.70%)</p> <p>1</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>aching joints</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>axillary lump</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>back pain</p>	<p>7 / 27 (25.93%)</p> <p>8</p> <p>1 / 27 (3.70%)</p> <p>1</p>		

subjects affected / exposed	5 / 27 (18.52%)		
occurrences (all)	9		
leg pain			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
leg cramps			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Osteoarthritis			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Infections and infestations			
common cold			
subjects affected / exposed	9 / 27 (33.33%)		
occurrences (all)	19		
flu symptoms			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	3		
viral infection			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	2		
infection urinary tract			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	5		
Skin infection			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
gum abscess			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
chest infection			
subjects affected / exposed	5 / 27 (18.52%)		
occurrences (all)	5		
wound infection			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		

Bronchitis			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
vaginal infection			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
oral thrush			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
thrush vaginal			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	3		
Ear infection			
subjects affected / exposed	3 / 27 (11.11%)		
occurrences (all)	3		
Influenza			
subjects affected / exposed	2 / 27 (7.41%)		
occurrences (all)	2		
cold sores			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	2		
throat infection			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	2		
post operative wound infection			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
tonsillitis			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
hook worm			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The current study has several limitations . The study had a significant drop out rate. This was not unexpected over a study of such long duration and may be a reflection of the fluctuation in impact of CCPP seen in this young group of patients.
--

Notes: